Most Women Don’t Link Eye Changes to Menopause: Johnson & Johnson Survey
Johnson & Johnson, Naomi Watts and the American Optometric Association are encouraging women to include eye health in the broader menopause conversation.
Johnson & Johnson, Naomi Watts and the American Optometric Association are encouraging women to include eye health in the broader menopause conversation.
Johnson & Johnson’s MONARCH Platform helps improve early lung cancer detection by enabling physicians to access and biopsy suspicious lung nodules that are difficult to reach with conventional bronchoscopy.
Firefly Bio’s Firelink DAC platform will help advance Johnson & Johnson’s strategy to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumours.
Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is currently approved in more than 40 countries, including the US, Europe and Japan, for the subcutaneous treatment of non-small cell lung cancer.
Johnson & Johnson plans a phased commercial rollout of the OTTAVA system with select customers in the United States while working in parallel to advance into additional indications.
Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.